Ritobegron

Drug Profile

Ritobegron

Alternative Names: KUC 7483 BS; KUC-7483; KUC-7483 CL

Latest Information Update: 03 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Boehringer Ingelheim; Kissei Pharmaceutical
  • Class Acetates; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Overactive bladder; Urinary incontinence

Most Recent Events

  • 27 Oct 2009 Phase-III clinical trials in Overactive bladder in Japan (unspecified route)
  • 31 Jul 2009 Kissei Pharmaceutical completes Phase-II trials in Overactive bladder
  • 06 Apr 2005 Phase-II clinical trials in Overactive bladder in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top